What if it took 100 days to make a safe and effective vaccine against any virus?
CEPI and the UK Government recently hosted the Global Pandemic Preparedness Summit to explore how we can respond to the next “Disease X”, by making safe, effective vaccines within 100 days.
Latest newsView All
CEPI and SK bioscience partner to advance mRNA vaccine technology to build vaccine library, enable rapid response against Disease X
Up to $40 million in funding committed to support development of mRNA-vaccine candidates against Lassa Fever virus and Japanese Encephalitis virus
The Race to Future-Proof Coronavirus Vaccines
To help humanity get ahead, we need vaccines that provide broad protection against new variants of COVID-19 as well as future coronavirus threats.
Could monkeypox give us an R&D blueprint to end pandemics?
Availability of smallpox countermeasures, developed to counter bioterrorism, also give the world the means to combat monkeypox and other Orthopoxviruses. What if this approach could be applied to all viral families?
CEPI funds NEC Group's broadly protective betacoronavirus vaccine
Up to $4.8m will support using artificial intelligence to develop new vaccine candidates.
What will it take for the world to develop, and enable access to safe and effective vaccines against new pathogens in 100 days? And why is it crucial that the world achieves this 100 Days Mission?
Disease surveillance networks
International viral surveillance networks will need to be established that can alert global authorities to emerging epidemic threats and swiftly share genetic and disease information to trigger vaccine development.
Prototype vaccine library
The world must produce a library of prototype vaccines and other biological interventions against the viral families known to infect people. This will enable rapid adaptation of these prototype vaccines for clinical testing and evaluation of safety and effectiveness.
Rapid-response vaccine technology
Rapid response technologies must be developed, which can be quickly adapted to develop vaccines against the next Disease X.
Boosting vaccine manufacturing
Global manufacturing capacity needs to be in place, particularly in lower income countries. New approaches to manufacturing need to be advanced to produce vaccines at the speed and scale needed to stamp out a pandemic threat.
Trial and regulatory procedures
A global network of clinical trial sites, labs, and a globally agreed set of “rules” for trials in a pandemic situation needs to be established. These trial approaches will help to streamline data sharing and vaccine approvals by regulators.
Architects of Change
The world must urgently work together to outpace emerging viral threats. If we unite across countries and across the public and private sectors, we can make pandemics a thing of the past. Join us.